Radiochemical pharmacokinetic profile of P10 peptide with antifungal properties

Author(s)

Faintuch, Bluma L. ^[1] ; Oliveira, Erica A. ^[1] ; Munoz, Julian E. ^[2] ; Travassos, Luiz R. ^[3] ; Taborda, Carlos P. ^{[2, 4]}

Affiliation

^[1] Inst Energy & Nucl Res, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Dept Microbiol, Inst Biomed Sci, BR-05508 Sao Paulo - Brazil

^[3] Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Lab Med Mycol, Inst Med Trop Sao Paulo, IMTSP Lab Invest Med 53, LIM 53, BR-05508 Sao Paulo - Brazil

• Document type: Journal article
• Source: Medical Mycology; v. 52, n. 5, p. 544-548, JUL 2014.
• Web of Science Citations: 0

Abstract

Paracoccidioidomycosis (PCM) is a chronic granulomatous disease that is caused by the thermally dimorphic fungus Paracoccidioides brasiliensis. It is endemic in some countries of Latin America and can cause a high-burden fungal infection with significant morbidity and mortality. The peptide P10, which demonstrates immune protection against experimental PCM, was radiolabeled with a radioisotope and evaluated in vivo. The radiolabeling was conducted to trace the pharmacokinetics of the molecule in principal organs and tissues. This was achieved with high radiochemical purity. Biodistribution and scintigraphic imaging showed fast blood clearance that was mainly renal; however, hepatobiliar excretion was also, with marked uptake in cervical lymph nodes. This profile may be useful for the development of a prophylactic drug or vaccine for patients exposed to PCM. (AU)

• FAPESP's process: 11/17267-4 - Evaluation of a vaccine based on peptide-P10 and the therapeutic effect when administrate in combination with antifungal drugs in the fibrose experimental murine model induzed with Paracoccodioides brasiliensis conidia
• Grantee: Carlos Pelleschi Taborda
• Support Opportunities: Regular Research Grants